NasdaqGM - Nasdaq Real Time Price USD
Summit Therapeutics Inc. (SMMT)
24.08
-0.12
(-0.50%)
As of 2:13:50 PM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in GBP | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 6 | 6 |
| Avg. Estimate | -0.07 | -0.08 | -0.3 | -0.39 |
| Low Estimate | -0.08 | -0.1 | -0.35 | -0.47 |
| High Estimate | -0.06 | -0.07 | -0.27 | -0.31 |
| Year Ago EPS | -0.07 | -0.06 | -0.25 | -0.3 |
Revenue Estimate
| Currency in GBP | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 9 | 9 | 9 | 8 |
| Avg. Estimate | -- | -- | -- | 20.07M |
| Low Estimate | -- | -- | -- | -42.88M |
| High Estimate | -- | -- | -- | 162.11M |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in GBP | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.05 | -0.05 | -0.06 | -0.07 |
| EPS Actual | -0.07 | -0.06 | -0.06 | -0.07 |
| Difference | -0.02 | -0.01 | -0 | 0 |
| Surprise % | -46.90% | -23.06% | -3.31% | 0.65% |
EPS Trend
| Currency in GBP | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.07 | -0.08 | -0.3 | -0.39 |
| 7 Days Ago | -0.07 | -0.08 | -0.31 | -0.41 |
| 30 Days Ago | -0.07 | -0.08 | -0.32 | -0.43 |
| 60 Days Ago | -0.07 | -0.08 | -0.31 | -0.41 |
| 90 Days Ago | -0.07 | -0.08 | -0.3 | -0.42 |
EPS Revisions
| Currency in GBP | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | 2 | 2 | 2 | 3 |
| Up Last 30 Days | 2 | 3 | 4 | 4 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| SMMT | 2.61% | -23.52% | -21.38% | -31.13% |
| S&P 500 | 12.50% | 3.24% | 7.95% | 13.84% |
Upgrades & Downgrades
| Maintains | Goldman Sachs: Buy to Buy | 5/2/2025 |
| Reiterates | JMP Securities: Market Outperform to Market Outperform | 4/28/2025 |
| Maintains | Jefferies: Buy to Buy | 4/25/2025 |
| Reiterates | Cantor Fitzgerald: Overweight to Overweight | 4/23/2025 |
| Upgrade | Citigroup: Neutral to Buy | 3/26/2025 |
| Initiated | Cantor Fitzgerald: Overweight | 3/21/2025 |
Related Tickers
VKTX Viking Therapeutics, Inc.
27.10
+0.33%
TGTX TG Therapeutics, Inc.
34.40
-1.32%
SRPT Sarepta Therapeutics, Inc.
37.07
-20.72%
CYTK Cytokinetics, Incorporated
33.58
-1.15%
RGLS Regulus Therapeutics Inc.
7.85
+0.26%
IOVA Iovance Biotherapeutics, Inc.
3.1100
+0.32%
IBRX ImmunityBio, Inc.
1.8950
-5.72%
VRTX Vertex Pharmaceuticals Incorporated
438.49
-2.56%
BBIO BridgeBio Pharma, Inc.
35.55
-3.76%
RXRX Recursion Pharmaceuticals, Inc.
4.2400
+2.05%